[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"castration-sensitive-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:castration-sensitive-prostate-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,86,108,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641941","phase-2-study-of-psma-targeted-therapy-and-androgen-receptor-suppression-in-low-volume-metastatic-prostate-cancer-sparkle-trial-100641941",false,"NCT07650240","Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial","A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer","SPARKLE","Inclusion Criteria:\n\n* Male patients aged 18 years or older\n* Signed informed consent must be obtained prior to participation in the study\n* Histologically confirmed adenocarcinoma of the prostate\n* Prior treatment with radical prostatectomy or radiation therapy for localized disease is required\n* Prior treatment with ADT or androgen receptor pathway inhibitor (ARPI) or cytotoxic chemotherapy is permitted if:\n\n  * The last treatment \\> 12 months from enrollment on the trial\n  * The duration of treatment is less than 3 months and no evidence of disease progression on treatment\n* Disease detected on PSMA PET\u002FCT scan \\[PSMA-avid low volume metastasis (LVM)\\]. Patients with standardized uptake value maximum (SUVMax) lesion\u002Fliver \\>1 \\[molecular imaging PSMA (miPSMA) score of 2\\] or lesion\u002Fparotid \\> 1 (miPSMA score of 3) would be included. PET scanners used in the study will comply with current guidelines established by the European Association of Nuclear Medicine (EANM) Research Limited (Ltd) (EARL) for harmonizing PET\u002FCT image acquisition and reconstruction\n* Patients with hormone sensitive low volume metastatic disease (LVM); either de novo metastatic or recurrent disease. LVM, as assessed on PSMA PET\u002FCT is defined as:\n\n  * =\\\u003C 10 total metastatic spots\n\n    * Lymph nodes with short axis of =\\\u003C 2.5 cm\n    * Total tumor volume (TTV) \\\u003C 200 mL\n  * =\\\u003C 4 bone metastases\n  * No brain or liver metastases\n* Eastern Cooperative Oncology Group (ECOG) performance 0 - 2\n* Hemoglobin \\>= 9 g\u002FdL\n* Platelet count \\>= 100,000\u002Fmm\\^3\n* Absolute neutrophil count \\>= 1,500\u002Fmm\\^3\n* Serum bilirubin =\\\u003C 1.5 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) =\\\u003C 2.5 x ULN\n* Serum creatinine =\\\u003C 1.5 x ULN or an estimated glomerular filtration rate (eGFR) \\>= 50 mL\u002Fmin\u002F1.73m\\^2\n* Able to start therapy within 28 days of screening\n* Expected life expectancy \\> 6 months\n\nExclusion Criteria:\n\n* PSMA-undetectable disease defined as rising prostate specific antigen (PSA) with absence of PSMA-positive lesions in PSMA PET\u002FCT imaging\n* PSMA-negative disease defined as lesions detected on imaging that are deemed concerning for active cancer metastasis with PSMA SUVmax less than liver and meeting specific size criteria: lymph nodes with short axis of \\>= 2.5 cm, visceral lesions with a solid appearance (soft tissue density) \\>= 1 cm, and bone metastases with a measurable soft tissue component \\>= 1 cm\n* Patient with in-field failure (disease recurrence in prostate bed after primary definitive prostatectomy or radiotherapy)\n* Patient with spinal metastatic disease-causing cord compression\n* Patient with prior disease progression on ADT \\[castration resistance prostate cancer (CRPC)\\]\n* Prior treatment with ADT or cytotoxic chemotherapy or ARPI within less than 12 months from enrollment on the trial\n* Prior treatment with ADT or ARPI or cytotoxic chemotherapy is permitted only if more than 3 months treatment duration and no evidence of disease progression on treatment\n* Patients with severe \\[Common Terminology Criteria for Adverse Events (CTCAE) grade \\> 2\\] xerostomia\n* Patients with well documented history of myelosuppression or renal disease that might impair their participation in the trial per medical advice\n* Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible\n* Estimated life expectancy \\\u003C 6 months\n* Concurrent serious medical co-morbidities as determined by study investigator and expected to impair participation in the study\n\n  * Subjects with female partners of reproductive potential are required to use effective, medically acceptable methods of birth control (e.g., spermicide in conjunction with a barrier such as a condom or sexual abstinence) while on this study, and for 14 weeks after the last dose of 177Lu-PSMA-617","MALE","18 Years",{"count":20,"type":21},202,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low volume metastasis) or that has come back after a period of improvement (recurrent). Standard of care treatment for prostate cancer usually includes androgen deprivation therapy, with or without abiraterone acetate and prednisone. Leuprolide acetate is a form of androgen deprivation therapy. It blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. 177Lu-PSMA-617 is a type of radioconjugate drug. Upon administration, vipivotide tetraxetan targets and binds to prostate specific membrane antigen (PSMA)-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is overexpressed on prostate tumor cells. Abiraterone acetate is a type of anti-androgen drug. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving 177Lu-PSMA-617 in combination with leuprolide acetate, with or without abiraterone acetate and prednisone, may be more effective at treating patients with recurrent or de novo low volume metastatic hormone-sensitive prostate cancer than giving leuprolide acetate alone.",[27,28,29,30,31,32,33,34,35,36,37,38],"Recurrent Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8","Castration-Sensitive Prostate Cancer","Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Prostate Cancer","Prostate Adenocarcinoma","Adenocarcinoma of the Prostate","Localized Prostate Carcinoma","Metastatic Prostate Cancer","Metastatic Prostate Adenocarcinoma","Advanced Prostate Cancer","Advanced Prostate Adenocarcinoma","NOT_YET_RECRUITING","2026-06-15",{"date":42,"type":43},"2026-06-17","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2030-12-30",{"name":49,"class":50},"Mayo Clinic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100566373","phase-2-study-of-recurrence-directed-therapy-rdt-with-or-without-androgen-deprivation-therapy-adt-in-patients-with-radio-recurrent-oligo-metastatic-hormonecastrate-sensitive-prostate-cancer-romcspc-100566373","NCT06654336","Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone\u002FCastrate Sensitive Prostate Cancer (romCSPC)","Phase II Randomized Trial of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Radio-recurrent Oligo-metastatic Hormone\u002FCastrate Sensitive Prostate Cancer (romCSPC).","RATIONAL","Inclusion Criteria:\n\n1. Previous biopsy-proven localized prostate adenocarcinoma (without predominant features of sarcomatoid, small cell or neuroendocrine carcinoma) treated with definitive or salvage radiotherapy ≥ 2 years or more before enrollment.\n2. Recurrent Oligo-metastatic CSPC, M0 on conventional imaging (bone scan and CT scan of chest\u002Fabdomen\u002Fpelvis) with ≤ 5 metastases cumulative on all imaging, including MRI and PSMA-PET.\n\n   Note: Patients with conventional imaging M1 oligometastatic CSPC, who have no more than 5 metastatic sites in all imaging modalities including MRI and PSMA-PET, will be accepted for study enrollment.\n3. All sites of recurrent disease must be amenable to treatment with radiotherapy or surgery in the judgment of the investigator.\n4. Biochemical recurrent prostate cancer with ONE of the following PSA recurrence definitions:\n\n   1. After definitive radiotherapy (prostate in situ), with PSA ≥ nadir + 2ng\u002Fml;\n   2. After prostatectomy and adjuvant\u002Fsalvage radiotherapy, with PSA ≥ nadir + 0.2ng\u002Fml.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18.\n2. ECOG Performance Status ≥3.\n3. PSA ≥ 20 ng\u002Fml.\n4. Treatment with ADT within 2 years from study enrollment or treatment with any androgen receptor axis within 6 months from study enrollment.\n5. Prior treatment with chemotherapy for prostate cancer or bilateral orchiectomy. Note: prior chemotherapy for a different type of cancer is allowed if the patient has been continuously disease-free for \\> 3 years.\n6. Intracranial or intrathecal metastasis.\n7. Spinal cord compression, or spinal intramedullary metastasis.\n8. Prior malignancy (except non metastatic, non- melanomatous skin cancer) unless disease free for \\> 3 years.\n9. Bilateral hip prosthesis, treated earlier with definitive prostate radiotherapy, who have evidence of local disease recurrence within the prostate and no option for salvage treatment with brachytherapy or surgery.\n10. Previous documented hypersensitivity to ELIGARD® or other GnRH agonist analogs of components of such preparations.",{"count":61,"type":21},162,[24],"The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate \u002F hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.",[32,65],"Castration Sensitive Prostate Cancer",[67,65,68,69,70,71,72,73,74],"Prostate adenocarcinoma","Recurrent Oligo-metastatic Castration Sensitive Prostate CancerSPC","Andrigen Deprivation Therapy","Eligard","Recurrence Directed Therapy","Radiotherapy","Bio-chemical recurrence","Androgen Deprivation Therapy","RECRUITING","2026-03-11",{"date":78,"type":43},"2026-03-13",{"date":80,"type":21},"2026-03-30",{"date":82,"type":21},"2031-06",{"name":84,"class":50},"Ontario Clinical Oncology Group (OCOG)",3,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":51},"100519475","phase-1-a-feasibility-study-evaluating-a-role-for-maintenance-therapy-in-patients-with-biochemically-progressive-castration-sensitive-prostate-cancer-on-intermittent-androgen-deprivation-therapy-100519475","NCT06044025","A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy","Inclusion Criteria:\n\n* 18 years of age or older.\n* History of prior prostatectomy and\u002For radiation therapy to the prostate.\n* Currently have rising PSA levels ≥ 0.2 ng\u002Fml if they have undergone radical prostatectomy, or a PSA ≥ nadir + 2 if they have received only radiotherapy. Patients who were not offered salvage radiotherapy as an alternative treatment will be considered ineligible (due to a high PSA, other medical concerns).\n* Currently have at least 2 consecutively rising serum PSA levels more than 1 week apart\n* Currently have a PSA doubling time \\\u003C 9 months obtained within 60 days of consent.\n* Eugonad with testosterone \\> 150 ng\u002Fdl at time of consent.\n* Prior ADT (including iADT) for up to 24 months in association with definitive treatment is permitted if completed at least 12 months prior to consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\n* Willing to take study agents at the dose specified with meals.\n* Willing to discontinue current vitamin\u002Fmineral supplements and use only those provided by study. Herbal supplements may still be used.\n\nExclusion Criteria:\n\n* Current Chronic Lymphocytic Leukemia (CLL), Monoclonal Gammopathy of Unknown Significance (MGUS), Renal Cell Carcinoma (RCC) or another cancer requiring active treatment. Indolent or stable malignancies such as non-melanoma skin cancers are allowed.\n* Any active or deteriorating liver or renal disease, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C or bone marrow deficiency.\n* Any history of allergic reactions attributed to turmeric, metformin, or other compounds of similar chemical or biologic compositions.\n* History of lactic acidosis or risk factors for lactic acidosis (e.g., renal impairment, concomitant use of carbonic anhydrase inhibitors such as topiramate, hypoxic states such as acute congestive heart failure, excessive alcohol intake, and hepatic impairment).\n* Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.","100 Years",{"count":94,"type":21},34,[96],"PHASE1","The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with castration sensitive biochemical progressive prostate cancer.\n\nThe main objectives are:\n\n* Assess the feasibility of the study population and enrollment.\n* Evaluate time to PSA relapse with nutritional intervention on iADT.\n\nParticipants who are receiving iADT will be dispensed Metformin and turmeric and complete a pill diary. Participants will also have blood and stool samples collected and complete quality of life questionnaires.\n\nThe long-term goal is to further assess the efficacy and safety of this nutritional regimen and the roles of metabolic syndrome, microenvironment\u002Fmicrobiome, and genomic vs epigenomic profiles in the care of these patients through a clinical trial.",[65],"2026-01-14",{"date":101,"type":43},"2026-01-15",{"date":103,"type":43},"2024-04-11",{"date":105,"type":21},"2028-10",{"name":107,"class":50},"University of Arkansas",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":51},"100509891","phase-4-evaluation-of-the-change-in-psma-expression-in-prostate-cancer-in-response-to-hormonal-therapy-100509891","NCT05919329","Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy","Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy","Inclusion Criteria:\n\n* Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed.\n* Participants must have confirmed prostate adenocarcinoma, histologically, or by combined imaging and biochemical markers.\n* Age \\>= 18 years. Given the nature of the disease in question, only men will be included. Members of all races and ethnic groups will be included.\n* Participants must have sites of prostate cancer showing uptake on an initial PSMA PET scan.\n* Participants are planned to receive hormonal therapy within eight weeks of the initial PSMA PET. The hormonal therapy agents include:\n\n  * For CSPC: GnRH agonists, GnRH antagonists, first-generation antiandrogen (e.g. bicalutamide), or androgen receptor (AR)-targeted agent (e.g. Abiraterone, Enzalutamide, Apalutamide, Darolutamide)\n  * For CRPC: this group of patients are typically on continuous ADT (GnRH agonists or antagonists), which will be continued, and the hormonal therapy they will be started on is an androgen receptor (AR)-targeted agent (e.g. Abiraterone, Enzalutamide, Apalutamide, Darolutamide)\n* Life expectancy \\> 3 months.\n* Cohort 1: Castration resistant prostate cancer with rising PSA (confirmed by two PSA values at least 1 week apart), testosterone \\\u003C 50 ng\u002FdL, on continuous ADT at least 4 months, no AR targeted agent in the prior 4 months.\n* Cohort 2: Castration sensitive prostate cancer with no ADT or AR targeted agents use in the past 12 months, testosterone \\>50 ng\u002FdL\n\nExclusion Criteria:\n\n* Uncontrolled serious infection.\n* Intercurrent illness or condition that would limit compliance with study requirements.\n* Participants who have undergone any cancer treatment other than the hormonal therapy (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the baseline PSMA PET and PSMA PET at day 28.",{"count":116,"type":21},80,[118],"PHASE4","This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.",[121,65,32],"Castration Resistant Prostate Cancer","2025-10-23",{"date":124,"type":43},"2025-10-24",{"date":126,"type":43},"2024-06-25",{"date":128,"type":21},"2030-09-01",{"name":130,"class":50},"OHSU Knight Cancer Institute",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100494392","phase-2-maximal-cytoreductive-therapies-on-post-treatment-metastases-in-pts-with-mhspc-during-apalutamide-plus-adt-treatment-100494392","NCT05717582","Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment","A Prospective Study of Maximal-Cytoreductive Therapies for Patients With de Novo Metastatic Hormone-sensitive Prostate Cancer Who Achieve Oligopersistent Metastases During Systemic Treatment With Apalutamide Plus ADT (CHAMPION Study)","CHAMPION","Inclusion Criteria:\n\n1. Able to understand and willing to sign the informed consent;\n2. Aged ≥18 years;\n3. Histologically or cytologically confirmed prostate adenocarcinoma (primary small cell carcinoma or signet-ring cell carcinoma of the prostate are not allowed, however adenocarcinoma with neuroendocrine differentiation accounting ≤10% is allowed);\n4. Newly diagnosed prostate cancer (within 3 months prior to enrollment);\n5. M1a\u002Fb disease with the presence of 1-10 visible metastases at diagnosis by conventional imagine including bone scan (ECT) and CT or MRI of the chest, abdomen, and pelvis;\n6. With initial systemic treatment of apalutamide plus ADT and willing and expected to comply with treatment and follow up schedule \\[No more than 2-month systemic treatment before enrollment (including ADT and ADT combined with short-term first-generation anti-androgen therapy (flutamide or bicalutamide); To maximize enrollment, patients who had started apalutamide plus ADT before enrollment are allowed into the study provided that they are otherwise eligible and therapy was initiated no longer than 2 months before enrollment\\];\n7. Fit to undergo cytoreductive radical prostatectomy and radiotherapy to the visible sites of metastases;\n8. ECOG PS score is 0-1;\n9. Adequate organ function;\n10. Life expectancy ≥ 12 months.\n\nExclusion Criteria:\n\n1. History of allergies, hypersensitivity, or intolerance to any drug used in the study;\n2. Had the contraindications or is intolerant to cRP or RT;\n3. Had any visceral metastases (brain, liver, lung etc.) on screening conventional imaging (bone scans, CT or MRI);\n4. Prior Received any of the following treatments for primary and metastatic prostate cancer;\n\n   1. \\>2-month ADT or first-generation antiandrogens (bicalutamide, flutamide etc.);\n   2. Any other novel hormonal therapies (enzalutamide, darolutamide, abiraterone etc.) except ≤ 2-month apalutamide plus ADT listed in inclusion criteria;\n   3. Any chemotherapy;\n   4. local treatment or metastatic treatment for primary prostate cancer or metastases;\n   5. Any immunotherapy (PD-L1 etc.), target therapy (PARPi etc), etc;\n5. History of seizure or known condition that may predispose to seizure;\n6. History of major surgery 4 weeks before enrollment;\n7. Had major cardiovascular and cerebrovascular diseases within 6 months prior to the start of the study;\n8. Any condition that could interfere with drug absorption(e.g. unable to swallow, chronic diarrhea etc. );\n9. Conditions of active infection;\n10. History of previous or current malignant disease, except for curatively treated tumors cured for more than 3 years;\n11. Patients who is currently undergoing other trials;\n12. Unwilling or difficult to cooperate with treatment and follow-up visit;\n13. Other sever conditions which could interfere with trial safety or results judged by the investigator.",{"count":140,"type":21},47,[24],"To assess the feasibility and safety of Maximal cytoreductive therapies in patients with de novo mCSPC who achieve ≤10 oligopersistent metastases on PSMA PET CT after initial 3-month systemic treatment with apalutamide plus ADT. Maximal cytoreductive therapies consist of 1.cytoreductive radical prostatectomy with\u002Fwithout PLND guided by post-treatment PET 2.metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases. All patients receive continuous systemic treatment with apalutamide plus ADT.",[35,29],"2023-02-04",{"date":146,"type":43},"2023-02-08",{"date":148,"type":21},"2023-05-01",{"date":150,"type":21},"2026-12-31",{"name":152,"class":50},"Fudan University",2]